基于数据挖掘及网络药理学探讨中药调控铁死亡抗非酒精性脂肪性肝病的作用机制

雨涵 蒋(陕西中医药大学，中国)
怡 唐(陕西中医药大学，中国)
国泰 王(陕西中医药大学附属医院，中国)

摘要

目的：探讨中药调控铁死亡治疗非酒精性脂肪性肝病（NAFLD）的潜在机制。方法：通过GenCards和DisGeNET数据库获取NAFLD相关基因，在FerrDb数据库获取铁死亡相关基因；使用STRING获得蛋白相作关系，并通过 Cytoscape3.10.1构建PPI网络，筛选核心中药并进行后续数据挖掘、网络药理学及分子对接验证。结果：经过筛选得到1592个NAFLD基因、242个铁死亡基因，两者与362个核心中药的有效成分取交集，获得24个共同靶点；PPI分析得到6个核心基因；KEGG分析得到111条信号通路；分子对接验证显示83.33%的结合能＜-5.0kal/mol，表明核心中药与核心基因靶点对接稳定。结论：本研究初步分析了中药调控铁死亡抗NAFLD的多成分、多靶点、多通路的作用特点，为NAFLD临床诊疗及其机制探索提供了理论依据。

关键词

中药；NAFLD；铁死亡；作用机制

参考

孟令涵,陶婧娜,徐春军,等.角药在治疗非酒精性脂肪性肝病中的应用[J/OL].现代中医临床,1-6[2023-11-30].

Guo X, Yin X, Liu Z, et al. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment[J].Mol Sci,2022,23(24):15489.

非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.

Wei M, Liu X, Tan Z, et al. Ferroptosis: a new strategy for Chinese herbal medicine treatment of diabetic nephropathy[J]. Front Endocrinol (Lausanne),2023(14):118800.

余臣祖,张朝宁,张燕.铁死亡在代谢相关脂肪性肝病中的作用研究进展[J].临床医学研究与实践,2023,8(32):191-194.

王超越,黄晓巍,王雨辰,等.中药治疗非酒精性脂肪性肝病研究进展[J].人参研究,2022,34(5):44-47.

Nan Zhou, Jinku Bao, Ferr. A manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations[J].Database,2020(3):21.

Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses[J].Curr Protoc Bioinformatics,2016(54):30-33.

Piñero J, Saüch J, Sanz F, et al. The DisGeNET cytoscape app: Exploring and visualizing disease genomics data[J].Comput Struct Biotechnol,2021(19):2960-2967.

UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023[J].Nucleic Acids Res,2023,51(1):523-531.

Jia A, Xu L, Wang Y. Venn diagrams in bioinformatics[J].Brief Bioinform,2021,22(5):108.

Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest[J].Nucleic Acids Res,2023,51(1):638-646.

Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res,2003,13(11):2498-2504.

Kong Q, Ma Y, Yu J, Chen X. Predicted molecular targets and pathways for germacrone, curdione, and furanodiene in the treatment of breast cancer using a bioinformatics approach[J].Sci Rep,2017,7(1):15543.

Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. Journal of cheminformatics,2014(7).

Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)[J]. Nucleic Acids Res,2022,50(1):216-221.

Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces[J]. Nucleic Acids Res,2021,49(1):1388-1395.

马青云,刘辰,杜海涛,等.基于高通量分子对接虚拟筛选SARSCoV-2 3CL水解酶中药小分子抑制剂及抗新型冠状病毒肺炎(COVID-19)的中药及其复方预测[J].中草药,2020,51(6):1397-1405.

袁文强,杨柳婵,陈晨,等.表没食子儿茶素没食子酸酯对结肠炎作用的网络药理学分析及分子对接验证[J].亚太传统医药,2023,19(12):157-164.

Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J]. Front Endocrinol (Lausanne),2023(13):1087260. Published 2023 Jan 16.

Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications[J]. Cell Res,2021,31(2):107-125.

Chen J, Li X, Ge C, et al. The multifaceted role of ferroptosis in liver disease[J].Cell Death Differ,2022,29(3):467-480.

Wu Q, Chen Z, Ding Y, et al. Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis[J]. Front Nutr,2022(9):1033129.

Zhou H, Ma C, Wang C, et al. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease[J]. Eur J Pharmacol,2021(898):173976.

Treatment and Exploration of Non-Alcoholic Fatty Liver Disease in Traditional Chinese Medicine[J]. Journal of Contemporary medical practice,2022,4(6).

Takashima M, Ichihara K, Hirata Y. Neuroprotective effects of Brazilian green propolis on oxytosis/ferroptosis in mouse hippocampal HT22 cells[J]. Food Chem Toxicol,2019(132):110669.

Bakrim S, Benkhaira N, Bourais I, et al. Health Benefits and Pharmacological Properties of Stigmasterol[J]. Antioxidants (Basel),2022,11(10):1912.

Xin Y, Li X, Zhu X, et al. Stigmasterol Protects Against Steatohepatitis Induced by High-Fat and High-Cholesterol Diet in Mice by Enhancing the Alternative Bile Acid Synthesis Pathway[J].Nutr,2023,153(7):1903-1914.

Baskar A A, Al Numair K S, Gabriel Paulraj M, et al. β-sitosterol prevents lipid peroxidation and improves antioxidant status and histoarchitecture in rats with 1,2-dimethylhydrazine-induced colon cancer[J].Med Food,2012,15(4):335-343.

Kashyap P, Shikha D, Thakur M,et al. Functionality of apigenin as a potent antioxidant with emphasis on bioavailability, metabolism, action mechanism and in vitro and in vivo studies: A review[J].Food Biochem,2022,46(4):13950.

Yu Z, Yang L, Deng S, et al. Daidzein ameliorates LPS-induced hepatocyte injury by inhibiting inflammation and oxidative stress[J]. Eur J Pharmacol,2020(885):173399.

代惠婷.木犀草素对四氯化碳诱导小鼠急性肝损伤的保护作用及机制研究[D].长春:吉林大学,2023.

Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives[J]. Metabolism,2019(92):121-135.

Yan Z, Miao X, Zhang B, et al. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease[J].Life Sci,2018(215):64-72.

赵崇如.癌症相关脂肪细胞调控IL-6/STAT3通路促进乳腺癌恶性进展的机制研究[D].武汉:华中科技大学,2022.

张华,寇萱萱,邓婧鑫,等.缺氧诱导因子1α(HIF-1α)/Yes相关蛋白（YAP）在非酒精性脂肪性肝病中的调控作用[J].临床肝胆病杂志,2023,39(9):2191-2197.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i4.17108